Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney disease study pulled before it even started

NCT ID NCT05774392

Knowledge-focused Sponsor: Target PharmaSolutions, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to observe people with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) to understand how the disease naturally progresses and how well current treatments work. It planned to enroll adults diagnosed with CKD or ESKD and follow their health outcomes. However, the study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

Apr 2025

An estimate. Start dates often move.

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include adults who are being managed for Stage 1-5 CKD or received a transplant for ESKD.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Disease Cohort Inclusion Criteria: * Adult\* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface Exclusion Criteria: * Death * Manual removal (sponsor or site request) * No EHR interface encounter \> 3 years Engaged Cohort Inclusion Criteria: * Adult \* patients diagnosed and managed for CKD/ESKD invited to participate * Ability to provide written informed consent Exclusion Criteria: * Patient expressed desire to withdraw consent to complete PROs * Failure to complete PROs within 24 weeks of initial invitation * Greater than 24 months lapse of survey completion after baseline surveys completed * Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage kidney disease Kidney disease, chronic

More trials for these conditions

Other studies related to the condition(s) this trial covers.